Transdermal drug patches offer the advantages of ease of use, painlessness,
disposability, control of drug delivery and avoidance of first-pass metabolism
by the liver. Advances in synthetic materials and patch design have led to
patches that are more esthetically acceptable and that are capable of
delivering sustained dosing of active compounds for several days in a smaller
package. Patches relying on passive transport mechanisms have been limited in
their ability to deliver new classes of drugs, but formulations employing
penetration enhancers, and patch designs incorporating microporation and
energy-assisted delivery are expanding the range of drugs that can be
effectively delivered transdermally. Growth in demand for drug patches is
being driven by several factors - factors with strong demographic and
population trend underpinnings. Further improvements to transdermal transport
and the introduction of new patch designs will keep this segment expanding
through 2015.
Highlights
Analyzes and evaluates prescription skin patch products and assesses risks
and market potential
Analyzes patch designs, technologies and patch development issues
Provides assessments of prescription skin patch products in two dozen key
market segments
Provides market data and forecasts to 2015
Profiles patch manufacturers, their product development activities and
strategies
Table of Contents
The Transdermal Drug Delivery Market Dynamics
Drug Patch Market Structure
Important Patch Drug Therapies
Transdermal Drug Packaging
Demand Drivers
Competitive Landscape
Factors Limiting Growth
Prescription Patch Design & Technology
Patch Architecture
Passive Transdermal Patch Design
Passive Patch Construction
Active Transport Patch Technologies
Evolving Prescription Patch Technologies
Prescription Patch Development Factors
The Design Cycle
Design Partnerships
Patch Product Testing
Trials and Submissions
Pharmacokinetics & Dosage Forms
Patch Manufacturing Dynamics
Patch Manufacturing Company Profiles
Drugs Currently Delivered in Approved Transdermal Patches
Buprenoorphine
Clonidine
Diclofenac
Estradiol
Estradiol/Norethrindone acetate
Fentanyl
Lidocaine
Mecamylamine
Methylphenidate
Nitroglycerin
Norelgestromin
Oxybutynin
Rivastigmine
Rotigotine (EU)
Scopolamine
Selegiline
Testosterone
Drugs in Development for Transdermal Patch Delivery Systems
Antivirals
CNS
Hormones
Metabolic
Pain Management
Prescription Patch Design & Acceptance Factors
Dosing and Rate Factors
Materials Compatibility
Clinical Trial Process
Biocompatibility
Market Factors
FDA Regulations
Rx-to-OTC Switching
New Patch Technologies
Skin Patch Revenue Models
FDA-Approved Patch Therapies - Analysis and Market Data
ADHD
Contraception
Cardiovascular/Angina
Depression
Hormone Replacement Therapy
Hypertension
Motion Sickness
Neurology
Osteoporosis
Pain Management
Emerging Patch Therapeutics - Opportunity and Risk Assessment
